HepaRegeniX
Key Facts
| Invested since | 2016 |
| Based in | Tübingen |
About the company
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). A first compound has recently started clinical development.
MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This new and unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
Do you want to
know more about this company?
HepaRegeniX in the news
zum Artikel
HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration
zum Artikel
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
zum Artikel
HepaRegeniX GmbH secures Series B Financing in excess of €11 Mio. to advance first drug candidate to the clinic
zum Artikel
HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases
More startups from Life Sciences
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
Research, development and marketing of high-precision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs.
HBOX Therapies has developed a technology that facilitates lung-protective treatment of respiratory patients, the patented platform technology HBOX (Hyperbaric Blood Oxygenation). The management team of HBOX Therapies consists of the …
Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, …
Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®. Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases …
cytena’s single-cell printer is a unique device for separating, sorting and handling of single biological cells. For the first time this method enables an automated, separation of single cells with …
Intelligent fluids GmbH is designing innovative high performance cleaning fluids for industrial application that are unique in the world. These intelligent fluids® are based on a groundbreaking, patented technology that …
Lignopure GmbH is a spin-off of the TU Hamburg that enables the valorization of Lignin, a byproduct of ethanol biorefineries and the pulp and paper industry, via a proprietary technology. …
GILUPI developed a nanostructured detector, which is temporarily inserted into the bloodstream. The aim is to spot specific blood cells in vivo and thus to detect diseases in a very …
